News
The changes would limit how insurers add patient diagnoses that trigger lucrative extra payments.
Bernstein SocGen Group analysts reiterated an ‘Outperform’ rating on Humana Inc. (NYSE:HUM) and a $313 price target. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback